Galderma gives better than expected 2026 guidance, shares rise

Company Overview - Galderma, a Swiss skincare company, reported a 17.7% growth in full-year net sales, reaching $5.21 billion [1] - The strongest growth was observed in the Therapeutic Dermatology segment, with sales increasing by over 50% due to the launch of the Nemluvio product [1] Future Guidance - The company provided an optimistic guidance for 2026, expecting net sales growth of 17% to 20% [1] - Galderma anticipates a core profit margin of approximately 26% on a constant-currency basis for 2026 [1] Market Reaction - Following the announcement, Galderma's shares rose by around 7% [1] - Analysts from Vontobel noted that the guidance was stronger than expected, contributing to the positive market response [1]